Diffusion Capital Partners (DCP)

Diffusion Capital Partners (DCP) is Turkey’s leading deep-tech fund, with a focused thesis on commercializing complex, high-barrier scientific innovations. The firm’s positioning is unusual in the Turkish venture market: rather than chase consumer or fintech, DCP partners with scientists to build companies around microfluidics, liquid biopsies, advanced materials, and AI-enabled life sciences tools. Check sizes of $250k to $1M reflect early-stage participation, often as a seed lead or co-lead in capital-light deep-tech rounds. Cellsway, the firm’s portfolio company building cancer diagnostic chips that analyze blood, is illustrative of the thesis.

The healthcare thesis is genuinely scientific. Sub-vertical interests include biotech, diagnostics, AI/ML in healthcare, and life sciences tools. The right founder is a researcher or technical co-founder with serious scientific credentials (PhD-level, often with publications) building a product where the moat is real biological or physical IP, not just software. AI is welcome where it is a layer on top of underlying physical or biological discovery. Founders building pure digital health, telemedicine, or consumer wellness will find the firm uninterested.

Geographically, Turkey’s deep-tech ecosystem is real but underdeveloped compared to its consumer tech scene; DCP fills a clear market gap. The firm has credibility with European deep-tech LPs and can help founders syndicate cross-border into European deep-tech funds for Series A and beyond. The Istanbul base means strong access to Turkish technical universities (Bogazici, METU, ITU) and to the country’s broader scientific research apparatus. For US-only founders without Turkish ties, the firm is not the natural partner.

The right entry path is via a Turkish university research office, a regional deep-tech accelerator, or a warm intro from an existing portfolio scientist or co-investor. DCP reads science seriously, so a deck without technical depth will be triaged. The pitch should lead with the scientific moat, the IP position, the development timeline, and a realistic regulatory and go-to-market plan. Be prepared for scientific diligence including literature reviews and outside scientific advisors.

Caveats. Deep-tech timelines are long; if you are a software founder expecting Silicon Valley-style 18-month milestones, DCP’s pace may feel slow. Turkish fund structures and FX dynamics complicate cross-border rounds; work with regional corporate counsel from day one. The firm is small enough that partner bandwidth is finite; do not approach without a clear thesis fit. For science-rooted founders building genuine deep-tech in healthcare and life sciences with Turkish or European ties, DCP is among the most thoughtful regional partners; for digital health or consumer health founders, look elsewhere.